State Of Wisconsin Investment Board Affimed N.V. Transaction History

State Of Wisconsin Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $204,135 - $345,781	-104,151 Reduced 49.55%	106,049 $218,000
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $72,186 - $154,548	31,800 Added 17.83%	210,200 $582,000
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $81,180 - $124,300	-22,000 Reduced 10.98%	178,400 $780,000
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $59,278 - $80,357	10,700 Added 5.64%	200,400 $1.24 Million
Q2 2021 Aug 12, 2021	BUY	$7.78 - $11.4 $322,092 - $471,960	41,400 Added 27.92%	189,700 $1.61 Million
Q1 2021 May 17, 2021	SELL	$5.12 - $8.48 $29,184 - $48,336	-5,700 Reduced 3.7%	148,300 $1.17 Million
Q4 2020 Feb 03, 2021	SELL	$3.16 - $7.03 $109,336 - $243,238	-34,600 Reduced 18.35%	154,000 $896,000
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $614,836 - $892,078	188,600 New	188,600 $639,000
Q1 2020 May 06, 2020	SELL	$1.44 - $3.02 $131,472 - $275,726	-91,300 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$2.67 - $3.65 $243,771 - $333,245	91,300 New	91,300 $268,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.